

## Phase III

**NSABP-P-2** Phase III Randomized Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer

**NSABP-B-35, ACOSOG-NSABP-B-35, CTSU, NCCTG-NSABP-B-35, SWOG-NSABP-B-35** Phase III Randomized Study of Anastrozole Versus Tamoxifen in Postmenopausal Women With Ductal Carcinoma In Situ of the Breast Undergoing Lumpectomy and Radiotherapy

**NCCTG-N02C1** Phase III Randomized Study of Risedronate for Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy for Primary Breast Cancer

**CALGB-40101** Phase III Randomized Study of Adjuvant Cyclophosphamide and Doxorubicin Versus Paclitaxel in Women With High-Risk Node-Negative Breast Cancer

**BIG-01-01, CAN-NCIC-MA24, EORTC-10011, EU-20216, IBCSG-28-02, ROCHE-B016348B, ROCHE-B016348C** Phase III Randomized Study of Trastuzumab (Herceptin) in Women With HER2-Positive Primary Breast Cancer

**UCLA-0109024, BCIRG-007, GENENTECH-UCLA-0109024, NCI-G02-2116, ROCHE-UCLA-0109024** Phase III Randomized Study of Docetaxel and Trastuzumab (Herceptin) With or Without Carboplatin in Women With HER2-Positive Stage IIIB, IIIC, or IV Breast Cancer

**CPMC-IRB-14069, NCI-G02-2127, NOVARTIS-CPMC-IRB-14069** Phase III Randomized Study of Zoledronate for the Prevention of Bone Loss in Premenopausal Women Receiving Adjuvant Chemotherapy for Early Stage Breast Cancer

**ECOG-2100, CAN-NCIC-E2100, CTSU, NCCTG-E2100, NSABP-E2100** Phase III Randomized Study of Paclitaxel With or Without Bevacizumab in Patients With Locally Recurrent or Metastatic Breast Cancer

**CALGB-79809, NCI-P01-0184** Phase III Randomized Study of Zoledronate, Calcium, and Cholecalciferol (Vitamin D) to Prevent Bone Loss in Women With Breast Cancer Receiving Adjuvant Chemotherapy

**CALGB-49907, CAN-NCIC-CALGB-49907, CTSU, ECOG-CALGB-49907, SWOG-CALGB-49907** Phase III Randomized Study of Adjuvant Chemotherapy Comprising Standard Cyclophosphamide, Methotrexate, and Fluorouracil (CMF) or Doxorubicin and Cyclophosphamide (AC) Ver-

sus Oral Capecitabine in Elderly Women With Operable Adenocarcinoma of the Breast

**SWOG-S0012, CTSU** Phase III Randomized Study of Standard Neoadjuvant Doxorubicin and Cyclophosphamide Followed by Weekly Paclitaxel Versus Weekly Doxorubicin and Daily Oral Cyclophosphamide With Filgrastim (G-CSF) Followed by Weekly Paclitaxel in Women With Inflammatory or Locally Advanced Breast Cancer

**SWOG-S9630, CALGB-49901, SWOG-9630** Phase III Randomized Study of Medroxyprogesterone Acetate Versus Observation for Prevention of Endometrial Pathology in Postmenopausal Women With Breast Cancer Treated With Adjuvant Tamoxifen

**ATLAS, EU-96064** Phase III Randomized Study of Prolonged Versus Shorter Adjuvant Tamoxifen in Patients With Curatively Treated Breast Cancer

**ACOSOG-Z0011, GUMC-00153** Phase III Randomized Study of Axillary Lymph Node Dissection in Women With Stage I or IIA Breast Cancer Who Have a Positive Sentinel Node

**RTOG-9804, CALGB-49801, CAN-NCIC-MA26, CTSU, RTOG-DEV-1026** Phase III Randomized Study of Whole Breast Radiotherapy Versus Observation With or Without Optional Tamoxifen in Women With Good-Risk Ductal Carcinoma In Situ of the Breast

**NSABP-B-31** Phase III Randomized Study of Doxorubicin and Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab (Herceptin) in Women With Node-Positive Breast Cancer That Overexpresses HER2

**CAN-NCIC-MA20** Phase III Randomized Study of Adjuvant Breast Radiotherapy With or Without Regional Radiotherapy in Women With Previously Resected, Early Stage, Invasive Breast Cancer

**NCCTG-N9831, CALGB-49909, ECOG-N9831, GUMC-00224, SWOG-N9831** Phase III Randomized Study of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel With or Without Trastuzumab (Herceptin) in Women With HER-2-Overexpressing Node-Positive or High-Risk Node-Negative Breast Cancer

**CAN-NCIC-MA27** Phase III Randomized Adjuvant Study of Exemestane Versus Anastrozole With or Without Celecoxib in Postmenopausal Women With Receptor-Positive Primary Breast Cancer

**IBCSG-24-02, BIG-2-02, NABCI-IBCSG-24-02** Phase III Randomized Study of Ovarian Function Suppression in Combination With Tamoxifen Versus Ovarian Function Suppression in Combination With Exemestane Versus Tamoxifen Alone in Premenopausal Women With Endocrine-Responsive Breast Cancer

**IBCSG-25-02, BIG-3-02, NABCI-IBCSG-25-02** Phase III Randomized Study of Triptorelin and Exemestane Versus Triptorelin and Tamoxifen in Premenopausal Women With Endocrine-Responsive Breast Cancer

**SWOG-S0230** Phase III Randomized Study of Goserelin for the Reduction of Premature Ovarian Failure in Women With Stage I-III A Hormone Receptor-Negative Breast Cancer Undergoing Adjuvant Chemotherapy

**SWOG-S0221** Phase III Randomized Study of Four Schedules of Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Patients With Node-Positive or High-Risk Node-Negative Breast Cancer

**SWOG-S0226** Phase III Randomized Study of Anastrozole With or Without Fulvestrant as First-Line Therapy in Postmenopausal Women With Metastatic Breast Cancer

**92381L/0048, NCT00065325** The Evaluation of the Efficacy and Tolerability of FASLODEX (fulvestrant) and AROMASIN (exemestane) in Hormone Receptor Positive Postmenopausal Women With Advanced Breast Cancer

*For more information on the above protocols, please call PDQ, a service on the National Cancer Institute, at 1-800-4-CANCER. The PDQ Web site is accessible at [www.cancer.gov/clinical\\_trials](http://www.cancer.gov/clinical_trials).*

*A searchable Web site developed by the National Library of Medicine is also available at <http://clinicaltrials.gov>.*